FORT LEE, N.J., Aug. 2, 2017 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has granted Enzychem Lifesciences, Corp. (KONEX:183490), the largest life sciences company in South Korea's KONEX Stock Exchange, to start its phase 2 study of EC-18, a synthetic palmitoyl-2-linoleoyl-3-acetyl-rac-glycerol (mosedipimod), the investigational new drug application (IND) Enzychem submitted to the Agency, to research its safety and efficacy in managing chemo-radiation induced oral mucositis (CRIOM).